Epilepsy with myoclonic-atonic seizures (EMAS) is a genetically determined neurological disorder characterized by specific types of epileptic seizures. The main feature of EMAS are myoclonic and atonic seizures, which can occur in patients at different ages. Myoclonic seizures reflect sudden, brief contractions of a muscle or group of muscles, while atonic seizures lead to a loss of muscle tone, contributing to falls and possible injuries. These types of seizures can be associated with other forms of epilepsy and require careful diagnosis to select the optimal treatment methods.
History of the disease and interesting historical facts
Epilepsy has been known to mankind since ancient times. In ancient times, it was perceived as a manifestation of divine intervention or mental disorder. Artifacts from ancient Egypt and Mesopotamia testify to the presence of such disorders, and in some cases, patients were subjected to various rituals and treatments based on mysticism. In the Middle Ages, myoclonic-atonic seizures were often associated with possession, which led to stigmatization and persecution. Modern research into epilepsy began only in the 18th and 19th centuries, when scientists such as Emil Kraepelin and John Hughes began to systematize symptoms and seizures, linking them to morphological changes in the brain.
Epidemiology
Epilepsy, including EMAP, is one of the most common neurological diseases. According to the World Health Organization, the epidemiology of epilepsy varies from 0.5% to 1% of the population in different regions of the world. Myoclonic-atonic seizures most often manifest in childhood, especially in children aged 5 to 10 years. In addition, according to a study published in the journal Epilepsy, there is a predisposition in males among patients with EMAP, which necessitates attention to this aspect in clinical practice.
Genetic predisposition to this disease
Research shows that EMAP has a significant genetic predisposition. Important mutations have been identified in genes responsible for ion channels, such as SCN1A, KCNQ2, and others. For example, mutations in SCN1A lead to abnormal functioning of sodium channels, which can increase neuronal excitability, contributing to the occurrence of seizures. Genetic tests can help in diagnosis and prediction of the disease development, but not all mutations have a clear correlation with clinical manifestations, which requires a comprehensive approach to patient assessment.
Risk factors for the development of this disease
There are various risk factors that contribute to the development of EMAP. These factors can be classified as follows:
- Physical factors:
- Head injuries
- Strokes, tumors and infectious diseases affecting the central nervous system
- Chemical factors:
- Scientifically proven studies show a link between the effects of toxic substances on the nervous system and the development of epilepsy
- Alcohol addiction and drug abuse can also contribute to seizures.
- Social factors:
- Family predisposition
- Social environment, stress and traumatic situations
Diagnosis of this disease
EMAT diagnostics is a multi-stage process, the main components of which are:
- Main symptoms: Myoclonic and atnic seizures, frequent falls, often without warning signs.
- Laboratory tests: Complete blood count, biochemical parameters, electrolyte levels.
- Radiological examinations: MRI and CT scans that can detect structural abnormalities in the brain.
- Other types of disease diagnostics: EEG (electroencephalography) to record the electrical activity of the brain.
- Differential diagnosis: Consideration of the possibility of other neurological disorders such as syncope or psychogenic seizures.
Treatment
Treatment of EMAP should be comprehensive and individualized, taking into account the severity of the disease and the potential for future epileptic seizures. Key aspects of treatment include:
- General treatment: Lifestyle, including diet, physical activity, avoidance of provoking factors (stress, overwork).
- Pharmacological treatment: Antiepileptic drugs such as lamotrigine, valproic acid, topiramate.
- Surgical treatment: In rare cases, surgery may be used to resect areas of the brain responsible for seizures.
- Other types of treatment: Neurostimulation and psychotherapy aimed at improving the general condition of the patient and reducing the frequency of attacks.
List of medications used to treat this disease
Effective drugs for the treatment of EMAP include:
- Lamotrigine
- Valproic acid (Valproate)
- Topiramate
- Clonazepam
- Retigabine
Disease monitoring
Monitoring of the condition of patients with EMAP includes:
- Control stages: Regular visits to a neurologist to assess the effectiveness of therapy and side effects
- Forecast: In most cases, the disease is treatable, but requires long-term monitoring.
- Complications: Possible development of cognitive impairment, mental disorders, and recurrent trauma due to seizures.
Age-related features of the disease
EMAP may present at different ages, and the specific course of the disease varies. Children are more likely to develop myoclonic-atonic seizures, while adults and the elderly may have an increased risk of concomitant neurological diseases and complications. Thus, early diagnosis and treatment are important for successful lifelong disease management.
Questions and Answers
- What are myoclonic-atonic seizures? This is a combination of myoclonic (sudden muscle contractions) and atnic (loss of tone) seizures, characteristic of a specific form of epilepsy.
- How is EMAP diagnosed? Diagnosis includes clinical data, medical history, EEG, MRI and blood tests.
- Is it possible to cure EMAP? A complete cure is not possible, but controlling seizures with medication and lifestyle can significantly improve a patient's quality of life.
- How to prevent falls during seizures? It is recommended to create a safe environment where the risk of injury is reduced, as well as to use special supporting devices.
- How will the disease affect the quality of life? EMAP can impact social and occupational aspects of life, but with good treatment and patient support, quality of life can be significantly improved.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov, a neurologist with many years of experience, advises:
- Have regular medical check-ups and discuss any changes in your condition with your doctor.
- Maintain a daily routine, including adequate sleep and nutrition.
- Keep a seizure diary to understand the triggers that contribute to their occurrence.
- Avoid situations that may contribute to stress and excessive fatigue.
- Participate in support groups to share experiences and information.
Epilepsy with myoclonic-atonic seizures is a serious disease that requires a comprehensive approach to diagnosis and treatment. Awareness of the disease, support of family members and timely referral to specialists can significantly improve the patient's quality of life.
